Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 1999

View Archived Issues

Licensing opportunity from NIH: oligonucleotides for enhancing the activity of antitumor drugs

Further positive results received from animal studies of La Jolla's xenotransplantation compound

Amylin's AC-2993 yields encouraging results in type II diabetes study

Boston Biomedica and UNC expand natural products agreement

Company Profile: UroGenesys

Elan: Q1 1999 highlights

Sugen: Q1 1999 highlights

Cortex's new AMPA function enhancer CX-691 receives patent coverage

Company Profile: Viron Therapeutics

Nine recently issued patents owned by Geron cover telomere and telomerase technology

FDA panel votes to recommend approval for Betapace

Afferon and Mundipharma collaborate on development of resiniferatoxin

Kissei prepares to file for approval of amprenavir in Japan

Allergan: Annual Report 1998/Q1 1999

Georgetown U. discloses new series with the ability to activate PKC

U.S. patent issued last month covers Warner-Lambert's new ECE inhibitors

Novel tricyclic inhibitors of protein farnesyltransferase claimed by Schering-Plough

Celltech reports new developments in the field of PDE4 inhibitors

Antithrombotic agents synthesized and tested at Roche

New acetamide derivatives developed at SS Pharm. for diabetic complications

HIV-1 TAT variants and their use in anti-AIDS therapy disclosed by Transgene

BioChem Pharma identifies novel lead NNRTI: BCH-1

Aceclofenac is effective and well tolerated in women with primary dysmenorrhea

Alendronate prevents LHRH analogue-induced bone loss

AstraZeneca updates status of robalzotan

Brazilian study evaluates potential utility of finasteride in women with hirsutism

Telomerase inhibitor identified during screening of microbial metabolites

AH-1058: new antiarrhythmic agent with unique profile of activity

Promising phase I/II results for Leuvectin in prostate cancer presented at AUA meeting

One-year data presented at urology meeting confirm efficacy of FemSoft for stress incontinence

Company Profile: Inhibitex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....